Cefiderocol for treatment of an empyema due to extensively drug-resistant <i>Pseudomonas aeruginosa</i>: Clinical observations and susceptibility testing considerations.

Kufel, Wesley D; Steele, Jeffrey M; Riddell, Scott W; Jones, Zachary; Shakeraneh, Pegah; Endy, Timothy P

Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: Clinical observations and susceptibility testing considerations.

Kufel, Wesley D; Steele, Jeffrey M; Riddell, Scott W; Jones, Zachary; Shakeraneh, Pegah; Endy, Timothy P.

Afiliação

Kufel WD; Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, NY, USA.
Steele JM; State University of New York Upstate Medical University, Syracuse, NY, USA.
Riddell SW; State University of New York Upstate University Hospital, Syracuse, NY, USA.
Jones Z; State University of New York Upstate Medical University, Syracuse, NY, USA.
Shakeraneh P; State University of New York Upstate University Hospital, Syracuse, NY, USA.
Endy TP; State University of New York Upstate Medical University, Syracuse, NY, USA.

IDCases ; 21: e00863, 2020.

Article em En | MEDLINE | ID: mdl-32577400

Palavras-chave

Antibacterial resistance; Cefiderocol; Pseudomonas aeruginosa; Siderophore; Susceptibility testing

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: IDCases Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google